With functions that range from cell envelope structure to signal transduction and transport, lipoproteins constitute 2 to 3% of bacterial genomes and play critical roles in bacterial physiology, pathogenicity, and antibiotic resistance. Lipoproteins are synthesized with a signal peptide securing them to the cytoplasmic membrane with the lipoprotein domain in the periplasm or outside the cell. Posttranslational processing requires a signal peptidase II (LspA) that removes the signal peptide. Here, we report the crystal structure of LspA from Pseudomonas aeruginosa complexed with the antimicrobial globomycin at 2.8 angstrom resolution. Mutagenesis studies identify LspA as an aspartyl peptidase. In an example of molecular mimicry, globomycin appears to inhibit by acting as a noncleavable peptide that sterically blocks the active site. This structure should inform rational antibiotic drug discovery.
T he threat of antibiotic resistance is recognized as a serious public health issue. Governments have introduced incentives to encourage work on anti-infectives by major drug makers in the face of a global rise in antimicrobial-resistant infections.
The enzymes involved in bacterial lipoprotein posttranslational processing ( Fig. 1 ) are essential in many pathogenic bacteria and have no equivalents in humans, making them potential drug targets (1) (2) (3) . LspA, as a key enzyme involved in the posttranslational processing of lipoproteins in Pseudomonas aeruginosa, an opportunistic human pathogen, is a target for antibiotic development (1, 4) . LspA does not have sequence homology to proteins of known structure. Globomycin, an antibiotic produced by select strains of Streptomyces, inhibits LspA (1) . This cyclic depsipeptide ( fig. S1 ) is an antimicrobial effective against Gram-negative bacteria. Synthetic analogs also inhibit the growth of Gram-positive bacteria, including methicillinresistant Staphylococcus aureus (MRSA) (5) .
P. aeruginosa has 175 lipoproteins, and presumably all are processed by LspA. The prolipoprotein substrates of LspA are cleaved at a four-residue consensus sequence (LAGC, L ) known as the lipobox that always ends with a cysteine, and the consensus allows for limited variability of the first three residues. In the prolipoprotein form, the cysteine is in thioether linkage to diacylglycerol (DAG). We refer to the dagylated cysteine as Cys*. The prolipoproteins consist of an N-terminal signal peptide that includes the first three residues of the lipobox and a C-terminal lipoprotein starting with the lipobox cysteine.
We sought to obtain a crystal structure of LspA so as to gain insights into its substrate binding and catalytic mechanisms. We conducted crystallization trials using recombinant LspA from P. aeruginosa (strain PAO1) expressed in Escherichia coli. Affinity and size-exclusion chromatography provided material of high purity ( fig. S2) (6) . LspA was crystallized by means of the in meso (lipid cubic phase) method (7) in the presence of globomycin ( fig. S2) . A structure of the complex was obtained at a resolution of 2.8 Å by using seleno-methionine, single-wavelength anomalous diffraction phasing (Fig. 2) . The seleno-methionine derivative was produced through in vivo and cellfree expression.
LspA is a small protein consisting of 169 amino acids (4) . It is a monomer in the crystal. Structurally, the protein can be broken down into two domains, each assembled from secondary structure elements from discontinuous stretches of the protein chain (Fig. 2) . The first consists of four transmembrane helices (MH1-4), with the N-and C-termini in the cytoplasm. The second is the periplasmic domain, which has two subdomains. The bigger of the two is a four-stranded, amphiphilic b-sheet that rests on the membrane. The sheet has the appearance of a cupped hand or cradle (b-cradle) that extends away from the helical core of the protein. Its hydrophobic surface is in contact with the membrane, whereas its polar surface faces the periplasm. The second Lipoproteins are synthesized as preprolipoprotein precursors via the Sec or TAT pathways, with an N-terminal signal peptide (green cylinder) securing them to the cytoplasmic membrane and the lipoprotein domain (green square) in the periplasm. Posttranslational processing requires, at a minimum, the sequential action of lipoprotein diacylglycerol transferase (Lgt) to lipid modify with a diacylglycerol and signal peptidase II (LspA) to remove the signal peptide. For some lipoproteins, the lipoprotein N-acyl transferase (Lnt) is required to N-acylate the N-terminal cysteine of the lipoprotein. LspA cuts in the lipobox, a consensus sequence of form LAGC* in which C* (yellow oval) has been dagylated by Lgt, to the amino side of the C*. Trafficking to the outer membrane uses the lipoprotein outer-membrane localization (Lol) pathway that involves the ABC transporter (LolCDE), a carrier chaperone (LolA), and a receptor (LolB), itself a lipoprotein. Lipoproteins reside mostly on the outer leaflet of the inner membrane and on the inner leaflet of the outer membrane facing into the periplasm. Some are located facing and in the extracellular space.
subdomain consists of a long loop with a single helical turn, the periplasmic helix (PH). The PH also sits on the membrane, with the long axis of the periplasmic PH loop orthogonal to that of the b-cradle.
Globomycin was modeled into a distinctive, donut-shaped region of electron density between MH2, MH3, and MH4 on the periplasmic side of the membrane (Fig. 2D) . The ligand density allowed unambiguous placement and orientation of the entire globomycin molecule, a 19-member cyclic depsipeptide that includes an a-methyl− b−hydroxy fatty acid, N-methyl-L-Leu (g·Leu), Lallo-Ile (g·Ile), L-Ser (g·Ser), L-allo-Thr (g·Thr), and Gly (g·Gly) ( fig. S1A) (5) . Globomycin is amphiphilic, with g·Ser and g·Thr comprising the polar half while the hydroxy fatty acid, g·Leu, and g·Ile make up the apolar half. As expected, the apolar half of globomycin extends into the membrane, and its polar end faces the interface. In the unbound state, molecular dynamics simulations (MDS) show globomycin partitions into the membrane oriented essentially as it is in the complex ( fig. S3 ). The PH loop sits over and blocks direct access from the periplasm to the active site, suggesting that globomycin first partitions into the membrane and then diffuses laterally into the active site to inhibit the enzyme. Conserved residues decorate the globomycin-binding pocket (Fig. 3A) , a region that has been implicated in peptidase activity.
Globomycin is firmly anchored to LspA by hydrogen bonds and hydrophobic interactions ( Fig. 3A and fig. S4 ). The most notable hydrogen bond is that between the b-hydroxy of g·Ser and the carboxyl of Asp 143 , tentatively identified as one of the catalytic dyad aspartates (8) . In MDS, this interaction persists throughout the 500 ns simulation. The backbone carbonyls of g·Leu, g·Ile, and g·Ser, to one side of the globomycin ring, face the protein and hydrogen bond with the side chains of strictly conserved Asn 112 and Arg
116
. The side chain of g·Leu, as well as the acyl chain of the hydroxy fatty acid, have extensive hydrophobic interactions with apolar residues in the protein (Fig. 2D ). These are particularly well developed in the case of the fatty acid, which is in close contact with the membrane-exposed surface of the PH and with residues on MH2. MDS confirms these interactions ( fig. S4 ).
We investigated LspA by means of MDS in the complex and apo forms. In both, the enzyme was stable in a palmitoyloleoylphosphatidylethanolamine (POPE): palmitoyloleoylphosphatidylglycerol (POPG) membrane through the 500 ns simulation (movies S1 and S2). In the apo form, simulations showed a minor rearrangement of the active site, with a network of hydrogen bonds emerging that involve Asn , all of which are strictly conserved residues. In addition, there was enhanced flexibility of the PH loop, which moved laterally at the interface while remaining anchored to the membrane by highly conserved Phe 59 and Phe
61
. If globomycin in the complex indicates the active site in LspA, an examination of this part of the protein immediately suggests how the prolipoprotein substrate orients itself for binding and Michaelis complex formation. The signal peptide helix of the prolipoprotein is the right size and shape to slot into the space between MH2 and MH4 of LspA (Fig. 3B ). Upon signal peptide helix binding, the lipobox of the substrate would sit in the active site similar to the g·Leu-g·Ile-g·Ser tripeptide of globomycin (Fig. 3C ) in the complex structure. The Cys* of the lipobox would now reside further up in the active site, positioning the lipoprotein in the periplasm (Fig. 3B) . With this alignment, the scissile GlyCys* bond is extended and positioned between the carboxyls of the proposed catalytic residues, Asp 124 and Asp
143
. The DAG modification on Cys*, with its long hydrophobic chains, must remain anchored in the membrane. An indication as to where its glycerol head group and one of the acyl chains might reside comes from a lobe of electron density modeled in the complex structure as a monoacylglycerol (MAG, the host lipid used for crystallization), which sits to one side of the active site in a groove between MH4 and the b-cradle ( fig. S5 ). Although host lipid density, at 2.8 Å resolution, is often poorly and incompletely defined, density for the active-site lipid is clearly present in all four molecules of the asymmetric unit extending to C7 or C8 of the MAG acyl chain in omit maps. We suggest that one of the DAG acyl chains of the prolipoprotein substrate occupies a similar position on LspA, helping position and orient the scissile bond in the active site. The above model for how the prolipoprotein substrate interacts with LspA is supported by MDS ( Fig. 3B and movie S3) . Residues 56 to 62, which include the PH, are highly conserved. This stretch of protein sits on the surface of the membrane directly over the active site (Fig. 2) and constrains extension of the substrate from the active site to the periplasm to a deep cleft between the b-cradle and PH loop subdomains. In this model, the Cys* of the substrate is clamped between the b-cradle and the PH loop, with the dipole of the PH aligned with the carbonyl oxygen of Cys* (Fig. 3B) .
Despite lacking the consensus Asp-Thr-Gly sequence of aspartyl proteases (9), LspA has been tentatively identified as an aspartyl endopeptidase (8) . In the absence of evidence to the contrary, we assume here that the catalytic mechanism is as described for other aspartyl proteases (9) . Accordingly, we envision Michaelis complex formation involving a conjunction in the active site of two aspartates, a catalytic water and the scissile bond. Using globomycin to demark the active site, two aspartate residues, Asp 124 and Asp
, with suitably poised side chain carboxyls are apparent in the structure that, in all likelihood, represents the catalytic dyad (Figs. 2 and 3) . We propose therefore that these aspartates play a general acid-base role, with the one closest to the proposed water [not seen in the complex but apparent in MDS (movie S4)] being charged and abstracting a proton from it, creating a nucleophile ( fig. S1C ). The nucleophile attacks the carbonyl carbon of the scissile bond, forming a tetrahedral intermediate. Protonation of the amide nitrogen in the scissile bond and rearrangement causes the tetrahedral intermediate to collapse and hydrolysis products to form. Separation of the substrate's binding moieties by means of proteolysis would logically result in a sharply lower binding affinity of the two reaction products as compared with substrate. The lipoprotein product is anchored in the membrane only by the DAG chains of its C-terminal Cys* and should readily diffuse out of the active site, resetting LspA for another round of catalysis. When it occurs, further processing of the signal peptide and lipoprotein products of the LspA reaction involves signal peptide peptidases and N-acylation by lipoprotein N-acyl transferase (Lnt), respectively (Fig. 1) .
Many aspartyl proteases are important drug targets. The hypertension regulator renin (10, 11) and HIV protease (9, 12) are examples. Of the thousands of inhibitors designed to target aspartyl proteases, most contain a noncleavable core structure of the hydroxyethylene or hydroxyethylamine type designed to recapitulate the tetrahedral intermediate in the proteolytic reaction ( fig. S2B ) (9) . For those that have been crystallized bound to target proteases, the hydroxyl group sits between and is within hydrogen bonding distance of the two catalytic aspartates. Strikingly, the hydroxyethylamide of g·Ser in globomycin incorporates elements of a noncleavable transition-state isostere ( fig. S1) (Fig. 3, B and C) . The prolipoprotein model has been exploited successfully in MDS ( Fig. 3B and movie S3 ). An analysis of deduced amino acid sequences of LspAs from 485 organisms having between 35 and 95% sequence identity with the signal peptidase II of PAO1 identified 14 strictly conserved residues (D23, K27, N54, G56, G108, A109, N112, R116, V122, D124, F139, N140, A142, D143). complex (Fig. 3A) . This lends credence to the location of both sites in the protein as identified in the complex structure. All strictly conserved polar residues are involved in a hydrogen-bonded network extending into the membrane between the two periplasmic subdomains ( fig. S6 ), which serves multiple purposes. It provides structural integrity and definition to the active and binding sites. At the same time, it positions and orients active-site residues optimally for K a modulation (where K a is the acid dissociation constant) and catalysis. Such a hydrogen-bonded network of polar residues facilitates access to the active site for catalytic water molecules from the periplasm, which was confirmed with MDS (movie S4). Mutagenesis studies performed on LspA from Bacillus subtilis identified six amino acidscorresponding to Asp , and Asp 143 in P. aeruginosa-as being important for activity (8) . Only Asp 23 was required for stability, suggesting that the other five residues were needed for catalysis, active-site geometry, or the recognition of prolipoproteins (8) . Four of the five residues map onto the proposed active site in the LspA-globomycin complex in ways that make sense. However, Asp 115 is a highly conserved residue on the periplasmic end of MH3 ( fig. S6) To test this hypothesis, we analyzed peptidase activity of LspA by means of SDS-polyacrylamide gel electrophoresis (SDS-PAGE), with the dagylated form of the preprolipoprotein inhibitor of cysteine peptidase (ICP) (13) as substrate (Fig. 4) fig. S7A . (H) Quantitative representation of the data in (G) based on gel image analysis. Assays were performed by using proICP (pICP) generated in situ by the DOPG-dependent dagylation of pre-proICP (ppICP) catalyzed by Lgt (suppplementary materials, materials and methods). The Lgt substrate pre-proICP appears as two closely spaced bands (ppICP and ppICP') ( fig. S7A) , with the higher-molecular-weight band the stronger of the two [best seen in (G)]. The relative intensities of the two bands vary from prep to prep, which is apparent in (A) to (C) and (G). The LspA product ICP also runs as a pair of bands (ICP and ICP') ( fig. S7A) . It is the integrated intensity of the well-resolved ICP band that is quantified on the gel by using ImageJ and reported in (D) to (F) and (H). The mobility of LspA is very similar to that of ppICP' . The mobility of the LspA mutants differs slightly from that of the wild-type enzyme, which (G) makes them visible on the gel to varying degrees, depending on the mutant (fig. S7B) .
compromise catalysis to different degrees (movie S5). The Arg 116 Ala mutant was inactive, as expected given Arg 116 's interaction with globomycin and its proposed role in orienting the lipobox backbone of the peptide substrate in the active site. Globomycin inhibited the enzyme (Fig. 4C) .
Synthetic analogs of globomycin have been tested for efficacy against a number of bacterial species as part of a structure-activity relationship study (5) . The most effective congeners, which were 10 times more potent than globomycin, were modifications in which the fatty acyl chain was lengthened. This finding makes sense in light of the complex structure in which a longer chain would provide for more extensive interactions with the apolar surface of MH2 (Fig. 2) . The hydroxyl group in g.Ser was shown to be essential for globomycin inhibitory activity, which agrees with this residue's proposed role in sterically blocking the active site.
P. aeruginosa has 175 different lipoproteins (4). Their signal peptide and lipoprotein parts differ greatly in size, sequence, and structure, and of the four residues in the lipobox consensus sequence, only the cysteine is strictly conserved. A feature common to all prolipoproteins is the dagylated lipobox cysteine in which the lipoprotein, the signal peptide, and the DAG modification converge (Fig. 3B) . The LspA structure reported here has grooves and clefts radiating about the active site with remarkable shape complementarity to this trigonal feature of the prolipoprotein substrate ( fig. S8 ). Upon docking, the scissile bond of the substrate sits in the active site of the enzyme poised for cleavage. Thus, although LspA is highly specific in terms of the proteolytic reaction it catalyzes, its impressive array of diverse substrates can be explained by a shape complementarity around the scissile bond likely shared by all prolipoproteins.
The complex structure reported here can be used to inform the design of globomycin analogs with improved binding, efficacy, selectivity, and pharmacokinetic properties. As an alternative, because LspA is an aspartyl endopeptidase, it is a suitable target with which to explore the thousands of inhibitors developed for other medically relevant aspartyl proteases (9, 12) . Although the sequence identity of LspA from P. aeruginosa and MRSA is only 32%, the majority of active-site residues are conserved. MDS of both the apo and globomycin-bound homology models of MRSA LspA show remarkable stability and fidelity to the observed dynamics of the crystal structure of P. aeruginosa LspA (fig. S9) . Together with the crystal structure presented here, these homology models should also prove useful for the design and discovery of antibiotics targeting Grampositive as well as Gram-negative bacteria.
Conserved residues in LspA surround the proposed active site where globomycin binds. They are networked to such a degree ( fig. S6 ) that mutations interfering with antibiotic binding there would likely also impair how the enzyme binds and cleaves substrate. Because antibiotics that do not elicit resistance are invaluable medically (14) , lessons in effective drug design might be learned from the Actinomycetes, microbes that may well have achieved this in globomycin.
